Ovine serum biomarkers of early and late phase scrapie
© Batxelli-Molina et al; licensee BioMed Central Ltd. 2010
Received: 27 May 2010
Accepted: 2 November 2010
Published: 2 November 2010
Transmissible spongiform encephalopathies are fatal neurodegenerative disease occurring in animals and humans for which no ante-mortem diagnostic test in biological fluids is available. In such pathologies, detection of the pathological form of the prion protein (i.e., the causative factor) in blood is difficult and therefore identification of new biomarkers implicated in the pathway of prion infection is relevant.
In this study we used the SELDI-TOF MS technology to analyze a large number of serum samples from control sheep and animals with early phase or late phase scrapie. A few potential low molecular weight biomarkers were selected by statistical methods and, after a training analysis, a protein signature pattern, which discriminates between early phase scrapie samples and control sera was identified.
The combination of early phase biomarkers showed a sensitivity of 87% and specificity of 90% for all studied sheep in the early stage of the disease. One of these potential biomarkers was identified and validated in a SELDI-TOF MS kinetic study of sera from Syrian hamsters infected by scrapie, by western blot analysis and ELISA quantitation.
Differential protein expression profiling allows establishing a TSE diagnostic in scrapie sheep, in the early phase of the disease. Some proteic differences observed in scrapie sheep exist in infected hamsters. Further studies are being performed to identify all the discriminant biomarkers of interest and to test our potential markers in a new cohort of animals.
Scrapie is a well-known prion-associated sheep encephalopathy that was identified in the XVIII century. Scrapie is a fatal neurodegenerative disease and related forms affect also humans (i.e., Creutzfeldt-Jakob disease) and cattle (i.e., bovine spongiform encephalopathy). It is characterized by accumulation in the central nervous system of a pathological agent, the prion protein (PrPSc) , which differs from the endogenous normal form (PrPc) in conformational changes, partial resistance to proteolytic degradation and insolubility in the presence of detergents [2, 3]. Scrapie is a good model to study transmissible spongiform encephalopathies (TSEs) since the disease is related to genetic factors. The natural occurrence of scrapie is associated with the PRNP genotype at positions 136, 154, 171 [4–6]. Specifically, infected animals present the homozygous PrPVRQ/PrPVRQ genotype, whereas healthy ones the homozygous PrPARR/PrPARR genotype. The incidence of the pathology is predicted as 100% for PrPVRQ/PrPVRQ animals whilst PrPARR/PrPARR animals are considered resistant [7–10]. However, few cases of scrapie in PrPARR/PrPARR sheep have been reported with biochemical and transmission characteristics similar to those of classic scrapie, although PrPSc was associated with lower proteinase K-resistance [11, 12]. In contrast to BSE, scrapie is associated with wide PrPSc dissemination in many non-neural tissues including the lymphoreticular system, the kidney and the placenta . The incubation period of the disease is long and silent (i.e., early, replicative phase of PrPSc) and clinical symptoms appear in sheep aged from twelve to fifteen months (i.e., late, neuroinvasion phase of the disease). PrPSc can be detected in PrPVRQ/PrPVRQ sheep two months after infection . Between three to six months after infection, the pathological agent is detected essentially in lymphoid formations associated to the gastrointestinal tract. From six to nine months the secondary lymphoïd organs are also infected and finally at the tenth month after infection the central nervous system is affected [6, 10, 15].
At the moment, unambiguous diagnosis is only possible post-mortem and it is based on the detection of PrPSc after proteolytic digestion. A complementary diagnostic evaluation can be performed by immunohistochemistry, western blot or ELISA but none of these methods can detect scrapie during the incubation period without autopsy. Since PrPSc can accumulate in lymphoid tissues before spreading to the nervous system and this accumulation can be very extensive, some authors have proposed using this tissue for the in vivo and post-mortem diagnosis of scrapie [16–20]. However, the sensitivity of this methodology is not well characterised because the magnitude and duration of lymphoid tissue involvement can vary considerably .
The diagnosis of TSEs during the early phase by a rapid test performed in blood is thus required because of the existence of the variant Creutzfeldt-Jakob disease in humans and its possible iatrogenic transmission by blood . Currently, several candidate ante-mortem biomarkers from serum, cerebrospinal fluid or tissue have been identified (i.e.,14.3.3 protein , NSE [24, 25], S100B proteins [26, 27], tau proteins [28–31], apolipoprotein E , C reactive protein and IL-6 , cystatin C , EDRF [35, 36]), but none of them is specific or sensitive enough to be used in a routine diagnostic test. The only useful marker for diagnostic tools still is PrPSc [37, 38], but its application in an ante-mortem test of prion disease in animals and humans, as proposed by Castilla and collaborators [39, 40], with the "Protein Misfolding Cyclic Amplification", is still difficult and no significant results are available yet. A new detection method of disease-associated multimeric forms of the prion protein in plasma of prion-affected hamsters and sheep is called 'Multimer Detection System' . The first results provided have now to be confirmed. Recently, the PrPSc has been detected in blood from sheep infected with scrapie and bovine spongiform encephalopathy  and in milk from ewes incubating natural scrapie .
We therefore decided to identify blood proteins that could be involved in scrapie development by analyzing a collection of serum samples from healthy and diseased sheep using proteomic tools. The classical proteomic tool, the bi-dimensional gel electrophoresis (2-DE) has been developed 25 years ago. Although this technique permits a high resolution separation of proteins, sensitivity and reproducibility of these experiments are not optimal to analyze hundred of highly variable animal samples. Moreover, 2-DE allows the separation of thousands of proteins but rare proteins are often not detected and low molecular weight proteins are not resolved. On the other hand, Surface Enhanced Laser Desorption/Ionization-time of flight-mass spectrometry (SELDI-TOF MS, Ciphergen Biosystems, Fremont, CA, USA), by combining selective protein binding with sensitive and quantitative mass detection, allows the evaluation of protein profiles in a short time from a large number of samples to identify putative biological markers [44–46]. SELDI-TOF MS was thus used to characterize the protein profile of sera from sheep at early (replication) and late (neuroinvasion) stages of scrapie. This analysis allowed us to identify a combination of biomarkers that discriminate between early phase (EP) and late phase (LP) of infection. We then validated these findings by assessing the appearance of differential markers in hamsters infected with the 263 K scrapie strain, a model of prion infection with shorter kinetics compared to sheep.
Scrapie evaluation and serum sampling
Clinical characteristics of control and diseased sheep
Age in months
7 to 95
Male and Female
Late phase scrapie (LP)
13 to 19
Male and Female
Early phase scrapie (EP)
7 to 10
Male and Female
Infection of Syrian hamsters with the 263 K scrapie strain
Infected animals were housed in controlled facilities fully compliant with the European policy on use of Laboratory Animals (agreement n°A3 4-175-28). The European guidelines (EC-86/609) for animal care and experimentations were followed throughout the duration of the study. They were identified by electronic chips. Ten age-matched Syrian hamsters were injected intra-peritoneally with 5 microliters (μL) (670 micrograms) of homogenate of brain infected by the 263 K scrapie strain diluted into 95 μL of phosphate buffer saline. 200 mg of infected brain has been crushed into 1.5 milliliters (mL) of 20% sucrose. Serum samples were taken at day 0, 29, 57, 106 and 150 post-infection. Each hamster was sacrificed at the end of the kinetics when it had lost ≈ 30% of its body weight and was no longer able to remain upright and feed by itself .
Serum protein fractionation
Blood was collected in dry tubes; coagulation was allowed by incubating samples at 37°C for 30 minutes. Following centrifugation, sera were immediately stored at -80°C.
Samples were pre-fractionated by anion exchange chromatography according to their charge characteristics, using the "Expression Difference Mapping Kit-Serum Fractionation" from Ciphergen Biosystems. Briefly, 20 μL of serum were added to each well of a 96-well culture microplate and proteins were denatured by addition of 30 μL of 9 M urea, 2% CHAPS, 50 mM Tris-HCl pH9. Then, each denatured aliquot was transferred into a filtration microplate containing in each well Q Hyper D F sorbent beads that had been previously rehydrated with 200 μL of 50 mM Tris-HCl pH9 (three times) and equilibrated with 1 M urea, 0.2% CHAPS, 50 mM Tris-HCl, pH9 (three times). In order to bind sample to sorbent, 50 μL of 1 M urea, 0.2% CHAPS, 50 mM Tris-HCl, pH9 buffer were added to each well and mixed for 30 minutes at 4°C. To collect th e six fractions we added sequentially 200 μL of 50 mM Tris-HCl with 0.1% OGP, pH9 (Fraction 1, F1) onto each well of the filtration microplate, then 200 μL of 50 mM Hepes with 0.1% OGP, pH7 (F2), then 200 μL of 100 mM sodium acetate with 0.1% OGP pH5 (F3), then 200 μL of 100 mM sodium acetate with 0.1% OGP pH4 (F4), then 200 μL of 50 mM sodium citrate with 0.1% OGP, pH3 (F5) and finally 200 μL of 33.3% isopropanol, 16.7% acetonitrile, 0.1% trifluoroacetic acid (F6, organic wash). Fractions were stored at -80°C.
SELDI-TOF MS analysis of sera
ProteinChip® CM10 (weak cation exchanger, Ciphergen Biosystems) were pre-treated with 5 μL of 0.1 M sodium acetate, pH4 twice. Five μL of each fraction were diluted in 5 μL of 0.1 M sodium acetate pH4 for use with weak cation exchanger (CM10) 8-spot protein chip arrays and incubated on a shaker in a humidified chamber at room temperature for 30 minutes. Spots were washed with 5 μL of 0.1 M sodium acetate pH4 twice for 5 minutes, followed by a quick rinse in de-ionized H2O. After air-drying, a sinapinic acid solution (70% acetonitrile, 0.1% trifluoroacetic acid) (SPA, Ciphergen Biosystems), prepared according to the manufacturer's instructions, was added to each spot. Arrays were analyzed with a PBS-II mass reader (Ciphergen Biosystems) using the SELDI 3.2.1 software (Ciphergen Biosystems). We performed the data acquisition of low molecular weight proteins by detecting the optimized size range between 2 and 20 kDaltons (kDa) with a maximum size of 30 kDa. Data were collected by averaging 60 laser shots with an intensity of 260 arbitrary units. The mass-to-charge ratio (m/z) of each protein captured on the array surface was determined according to externally calibrated standards (Ciphergen Biosystems): Hirudin BHVK (7034 Da), bovine Cytochrome C (12 230 Da), equine Myoglobin (16 951 Da) and bovine Carbonic Anhydrase (29 023 Da).
All spectra were compiled and qualified mass peaks (signal-to-noise ratio > 5) with mass-to-charge ratios (m/z) between 2 kDa and 30 kDa were auto-detected. Peaks clusters were completed using second-pass peak selection (signal-to-noise > 2) within 0.3% mass windows and estimated peaks were added. To avoid matrix interference, we removed all signals below 2 kDa and peaks intensities were normalized to the total ion current of m/z between 2 kDa to 20 kDa. Analyses were performed using the Protein Chip Software 3.2.1 (Ciphergen Biosystems).
Differential analysis of peak intensities
All normalized spectra were exported into an expression matrix N × M where N represents the mass peak and M the serum sample; the relative intensity of each peak is available. Peaks were selected by their statistical significance using the "Significance Analysis of Microarray" method (SAM) , a parametric method based on a modified Student's t-test currently used in genomic analysis. Significant peaks were selected when their score deviated from the average score obtained after 2000 permutations of matrix. The accuracy of markers and their discriminatory power were evaluated through Receiving Operating Characteristics (ROC) curves analysis . ROC curves are graphical visualizations of the reciprocal relation between sensitivity (Se) and specificity (Sp) of a test for various values. The Area Under the Curve (AUC) is a good evaluation of the combination of Se and Sp for a given test.
The best markers were combined to increase their Se and Sp with the mROC program  and with two supervised learning algorithms, AdaBoost  and Support Vector Machine (SVM) [52, 53]. The mROC program calculated the linear combination which maximized the area under the ROC curve for all selected variables (peaks). The equation for the respective combination was provided and could be used as a new virtual marker. For a marker combination and for a sample selected, the cut-off was the resulting value of the linear equation corresponding and calculated by the mROC program: Cut-off = a × Marker1 + b × Marker2 + c × Marker3, where a, b and c are coefficients. For this approach, data were previously transformed using the Box-Cox transformation to ensure a normal distribution .
The AdaBoost algorithm, short for Adaptive Boosting, is a machine learning algorithm formulated by Yoav Freund and Robert Schapire . It is a meta-algorithm and can be used in conjunction with weak learning algorithms (as decision tree) to improve their performance. In addition, it is less susceptible to the overfitting problem than most learning algorithms. SVM has been recognized as the most powerful classifier in various applications of pattern classification. For binary classification, it performs classification tasks by constructing hyperplanes in a multidimensional space (via a kernel function) that separate two classes of data with the maximum margin.
To estimate the errors prediction of these classifiers, we used the 10-fold cross-validation method. To avoid over-fitting problems and to reduce variance, we repeated this 10-fold cross-validation procedure 10 times. For this approach, we used the "ipred package" and the "e1071-package" of the R software .
The p values were calculated by one way ANOVA or Wilcoxon test with Kaleidagraph 4.0 software.
SELDI peak identification
The libraries of 48 sorbents were obtained from Sigma Aldrich (St Louis, MO, USA) and from Bio-Rad Laboratories (Hercules, CA, USA), as well as materials for electrophoresis such as plates and reagents.
Chromatography purification of the 12 030 Da (S10) biomarker from crude sample "F6"
After screening the libraries of 48 sorbents (10 μL each) on a NUNC SilentScreen 96-filter plate at two different pH binding conditions (5 and 8), two complementary sorbents were chosen to selectively interact at pH8 with either the 12 030 Da target (DEAE-Macroprep from Bio-Rad) or with the target impurities (immobilized arginine from Sigma Aldrich).
Screening was monitored by SELDI-TOF MS on CM10 arrays.
First, 500 μL of F6 sample diluted ten times in binding buffer (0.1 M Tris-HCl pH8, 0.15 M sodium chloride) were incubated in a Supelco spin column with 1 mL of arginine sorbent. Non-retained or flow-through fraction (FT), containing the 12 030 Da target, but now free of key impurities, was obtained by centrifugation (500 g for 5 minutes). Then, the FT fraction (5 mL) was poured in a 15 mL Falcon tube and 10 μL of DEAE-Macropep sorbent was added. Incubation was performed by gentle vertical stirring at room temperature for one hour. After incubation, FT fractions were centrifuged (1000 g for 10 minutes), beads transferred in a 500 μL microtube, extensively washed with 500 μL of binding buffer and the enriched 12 030 Da biomarker was sequentially eluted with 25 μl of the following eluents: a) 4.5 M urea, 1% CHAPS; b) 9 M urea, 2% CHAPS; c) 9 M urea, 2% CHAPS, 2.4% ammonium hydroxide. Elution was monitored by SELDI-TOF MS on CM10 arrays, and the most enriched 12 030 Da fraction (c) selected for final purification on SDS-PAGE after pH neutralization with acetic acid.
Preparative final purification of 12 030 Da marker by SDS-PAGE
25 μL of each enriched sample were mixed with 25 μL of Laemmli buffer (4% SDS, 20% glycerol, without reducing agent, 0.004% bromophenol blue and 0.125 M Tris-HCl, pH approx. 6.8) from Bio-Rad. The mixture was heated in boiling water for 2 minutes and immediately loaded on the gel. The SDS-PAGE gel was composed of a stacking gel (125 mM Tris-HCl, pH6.8, 0.1% SDS) with a large-pore polyacrylamide gel (4%) cast over the resolving gel (4-20% acrylamide gradient in 375 mM Tris-HCl, pH8.8, 0.1% SDS buffer). The cathodic and anodic compartments were filled with Tris-glycine buffer, pH8.3, containing 0.1% SDS. The electrophoretic run was done at 100 V until the dye front reached the bottom of the gel. Staining and de-staining were performed using the Colloidal Coomassie Blue staining kit from Invitrogen (Carlsbad, CA, USA). Putative blue bands were excised and split in two. The smallest part (one fourth) was to confirm the presence of the 12 030 Da biomarker by SELDI-TOF MS (NP20 array), after protein extraction with a solution of formic acid (5 vol)-acetonitrile (2.5 vol)-2-propanol (1.5 vol)-water (1 vol) for 2 hours at room temperature. The other part (three fourth) was trypsinized for protein identification by Liquid Chromatography MS/MS (LC-MS/MS) (see details in the corresponding section).
Analysis of crude and purified fractions by SELDI-TOF MS
After protein extraction, fractions at appropriate concentration, i.e. 0.02 μg/μL, were deposited upon ProteinChip® array surfaces, using a Bioprocessor device. Two types of arrays were selected: CM10 (weak cation exchanger) and NP20 (silica surface used in Matrix Assisted Laser Desorption Ionization time of flight, MALDI-TOF mode). Each array contained eight distinct spots over which the adsorption of protein could be performed. After applying the samples, the chip surfaces were washed to remove non-associated protein (only for CM10 arrays) and then dried and prepared for analysis after application of 1 μL of energy adsorbing matrix solution composed of a saturated solution of sinapinic acid in 50% acetonitrile and 0.5% trifluoroacetic acid. All arrays were then analyzed with a PCS 4000 ProteinChip® MS reader. The instrument was used in a positive ion mode, with an ion acceleration potential of 20 kVolts and a detector gain voltage of 2 kVolts. The mass range investigated was from 3 kDa to 20 kDa. The laser intensity was set between 200 and 250 units according to the sample tested. The instrument was mass calibrated with a kit of standard mass mixture "All-in-1 protein standard" (Bio-Rad).
Protein identification by LC-MS/MS
Putative blue bands manually excised from the gel were sent to the Functional Proteomic Platform in Montpellier (INRA, France) and protein identification was done according to a standard operating procedure. Tryptic peptides were analyzed by an ESI-Ion Trap mass spectrometer (Esquire HCT; Bruker Daltonik GmbH, Bremen, Germany), interfaced with an HPLC-Chip system (Agilent Technologies, Palo Alto, CA). A sample volume of 2 μl was loaded onto a C-18 enrichment cartridge (40 nL) with a flow rate of 0.3 μl/min of 0.1% (v/v) formic acid. After pre-concentration and clean-up, peptides were separated in the column (HPLC-Chip C18, 5 μm, 75 μmx43 mm, 40 nL enrichment column; Agilent Technologies, Palo Alto, CA) at a flow rate of 4 μl/min using a gradient of 3% to 80% (v/v) acetonitrile in 15 minutes (0.1% [v/v] formic acid). Peptides were eluted into the High Capacity ion Trap (Esquire HCT; Bruker Daltonik GmbH, Bremen, Germany). Capillary voltage was 1.5-2 kVolts in the positive ion mode and a dry gas flow rate of 4.5 L/minute with a temperature of 250 °C was used. The first full-scan mass spectrum was measured for a range from 310 to 1800 m/z. The second scan was done to exactly measure the Mr of the three major ions with higher resolution and the third scan to measure the collision-induced MS/MS spectrum of the selected ions. Theorical peptide values were obtained from UniProt database , the corresponding access number of ovine transthyretin is P12303.
Detection by SELDI-TOF MS of proteins which are differentially expressed in scrapie
List of the 15 biomarkers that were differentially expressed in scrapie sheep in comparison to control animals
Healthy (n = 65) vsEP (n = 55)
Healthy (n = 65) vsLP (n = 43)
Then, 43 serum samples from 13-19 month/old PrPVRQ/PrPVRQ sheep with LP scrapie were compared to the 65 serum samples from healthy, PrPARR/PrPARR animals. In LP scrapie, animals develop clinical symptoms (fear, nervousness, ataxia of the hind limbs, nibbling and licking) as the central nervous system is affected. Among the ten peaks differentially expressed in LP animals, four (i.e., S1 4030 Da, S5 3895 Da, S6 7690 Da and S7 9425 Da) were chosen as putative LP biomarkers (see Table 2 for statistical data). Three peaks (S1, S6 and S7) were over-expressed and one peak (S5) was under-expressed in LP sheep compared to controls. Their significant SAM values were ≥ 1.44 and the fold change was ≥ 1.26 or 0.38. Moreover, the biomarker accuracy test (ROC) of the four peaks showed an AUC > 0.617 with the following individual values: 0.617 (S1), 0.702 (S5), 0.659 (S6) and 0.693 (S7). The distribution of the intensity values of S1, S5, S6 and S7 (Figure 4B) confirmed the over-expression of markers S1, S6, S7 and the under-expression of marker S5 in LP sheep in comparison to healthy controls.
In conclusion, 7 peaks were found to significantly differentiate EP from control or LP animals and 10 peaks to significantly discriminate LP from control or EP animals. All together 15 different peaks were selected and 2 peaks (S1 and S13) were found to be significant in both phases of the disease.
EP and LP biomarkers panel best combination
Diagnostic performances of biomarkers combination using three different classifiers
Healthy (n = 65) Vs EP (n = 55)
Healthy (n = 65) Vs LP (n = 43)
Analysis of the appearance of serum biomarkers in VRQ/VRQ Cheviot TSE free sheep
Analysis of the appearance of serum biomarkers in hamsters infected with the 263 K scrapie strain
Identification and validation of S10 biomarker in sheep
In this study, we report the first analysis of potential biomarkers in serum of sheep during the first 7 to 10 months of scrapie infection. Our results indicate that we have detected a biomarker profile which could be used to diagnose scrapie in sheep with no apparent symptoms during the incubation phase of the disease. This is important as access to serologic markers can avoid invasive acts as biopsy or lumbar punction; however, complementary research is needed to confirm the real relevance of these proteins as TSEs biomarkers. Particularly, age matching is not fully balanced since it was difficult to find a large cohort of young control sheep. A validation study with age-matched animals will permit to confirm the robustness of the results. The main bottle-neck of SELDI-TOF MS profiling technology is the purification and the identification of individual proteins, therefore we need to concentrate our resources on biomarkers that are most likely to be biologically significant, such as the 4-protein signature we detected in EP sera. Conversely, the specificity and sensitivity of the combination of LP markers is not sufficient enough to exploit them further.
The kinetic study of the proteomic content of sera from hamsters infected with the 263 K scrapie strain allowed the detection of three differentially expressed peaks (H1, H2, H3). H1 increased early and regularly during the course of the disease, whereas H2 and H3 increased suddenly at very end of the infection process. None of these biomarkers was found to increase in control, not infected hamsters. Interestingly, S10 and H1 have the same molecular mass, but their intensities vary differently in sheep and in hamsters along time. S10 was then identified as a fragment of the transthyretin monomer. Transthyretin or pre-albumin is a homo-tetramer glycoprotein synthesized by liver and present in plasma, serum and cerebrospinal fluid. It has a molecular mass of 55 kDa and is the main thyroxin and vitamin A transporter. Transthyretin is an early marker of under-nutrition; its plasma level is decreased in case of liver failure, inflammatory syndrome and increased in case of chronic renal insufficiency. Transthyretin was already quoted in literature as a molecule associated with neurological disorders like multiple sclerosis , amyloid polyneuropathy [58–60] and TSEs . It has been previously described as a Creutzfeldt-Jakob disease biomarker detectable in the cerebrospinal fluid . Furthermore, several proteins linked to neurodegenerative diseases, such as amyloid beta, tau, prions and transthyretin, were found to be glycated in patients, and this is thought to be associated with increased protein stability through the formation of crosslinks that stabilize protein aggregates . A proteic characterization of the transthyretin fragment found discriminant in our study can provide useful informations for TSEs diagnostic. The molecular mass of the transthyretin monomer is 15.7 kDa; therefore by SELDI-TOF MS we detected a major fragment of the monomer. In scrapie sheep, its intensity decreased with the disease, whereas it increased in infected hamsters. Furthermore, sample handling can play a role in proteomics variations . Finally, since in hamsters scrapie is not a naturally occurring disease, different pathological mechanisms, and hence different protein signatures, could play a role in the development of the disease. Unfortunately, due to volume limitations, we could not identify the 12 030 Da SELDI peak in hamster serum for cross-validation. The transthyretin analysis done by western blot and serum level quantification confirmed the SELDI-TOF MS results. In a recent study, a training set of biomarkers has been established in brain homogenate samples from a murine model infected by the ME-7 scrapie strain . Two of the biomarkers found discriminant in the infected animals compared to controls may correspond in m/z to the biomarkers S12, H3 (7555 Da) and S14 (9180 Da). Their fluctuation is inversely correlated with S12 and S14, confirming that depending on the model and the time course study, biomarkers can be significantly down or up regulated and that protein expression in TSE disease exist across different species. The biomarkers we identified can be used as a target of development of future immunobased assay more suitable for veterinary or clinical analysis and compatible with blood screening.
Currently, the quest of non invasive TSEs biomarkers remains important and the development of a rapid, sensitive, specific, ante-mortem test is still needed. Indeed, a recent report detailed that prions adhere to soil minerals and remain infectious  such that unidentified environmental reservoirs of infectivity contribute to the natural transmission of prion diseases in sheep, deer and elk. Although the pandemic infection is now minimized, we need to remain vigilant to prevent a new crisis. The development of non-prion protein biomarkers for TSEs has been reported recently due to the advances in post-genomic technologies. However, more work needs to be done to confirm the specificity and sensitivity of bioassays combining the identified biomarkers. The remaining steps will be to design specific probes against biomarkers and optimize bioassay condition. Then, large scale validation would be affordable. These steps are mandatory to envision a future peripheric TSE bioassay.
List of abbreviations
- (PrP Sc ):
Pathological Prion Protein
- (PrP c ):
Normal Prion Protein
Transmissible Spongiform Encephalopathies
- (SELDI-TOF MS):
Surface Enhanced Laser Desorption/Ionization-time of flight-mass spectrometry
- (μL) :
Significance Analysis of Microarray
Support Vector Machine
Area Under the Curve
Receiving Operating Characteristics
Liquid Chromatography-mass spectrometry
- (MALDI-TOF MS):
Matrix Assisted Laser Desorption Ionization-time of flight-mass spectrometry
We thank the Functional Proteomic Platform in Montpellier (LPF, INRA, France) and particularly Delphine Centeno and Michel Rossignol for the identification of the transthyretin protein. We particularly thank Jean-François Delagneau for his implication and scientific help.
- Prusiner SB: Prions. Proc Natl Acad Sci USA. 1998, 95 (23): 13363-13383. 10.1073/pnas.95.23.13363.PubMed CentralPubMedView ArticleGoogle Scholar
- Griffith JS: Self-replication and scrapie. Nature. 1967, 215 (105): 1043-1044. 10.1038/2151043a0.PubMedView ArticleGoogle Scholar
- Prusiner SB: Novel proteinaceous infectious particles cause scrapie. Science. 1982, 216 (4542): 136-144. 10.1126/science.6801762.PubMedView ArticleGoogle Scholar
- Belt PB, Muileman IH, Schreuder BE, Bos-de Ruijter J, Gielkens AL, Smits MA: Identification of five allelic variants of the sheep PrP gene and their association with natural scrapie. J Gen Virol. 1995, 76 (Pt 3): 509-517. 10.1099/0022-1317-76-3-509.PubMedView ArticleGoogle Scholar
- Smits MA, Bossers A, Schreuder BE: Prion protein and scrapie susceptibility. Vet Q. 1997, 19 (3): 101-105.PubMedView ArticleGoogle Scholar
- Elsen JM, Amigues Y, Schelcher F, Ducrocq V, Andreoletti O, Eychenne F, Khang JV, Poivey JP, Lantier F, Laplanche JL: Genetic susceptibility and transmission factors in scrapie: detailed analysis of an epidemic in a closed flock of Romanov. Arch Virol. 1999, 144 (3): 431-445. 10.1007/s007050050516.PubMedView ArticleGoogle Scholar
- Hunter N: Natural transmission and genetic control of susceptibility of sheep to scrapie. Curr Top Microbiol Immunol. 1991, 172: 165-180.PubMedGoogle Scholar
- Hunter N, Goldmann W, Foster JD, Cairns D, Smith G: Natural scrapie and PrP genotype: case-control studies in British sheep. Vet Rec. 1997, 141 (6): 137-140. 10.1136/vr.141.6.137.PubMedView ArticleGoogle Scholar
- Hunter N: PrP genetics in sheep and the applications for scrapie and BSE. Trends Microbiol. 1997, 5 (8): 331-334. 10.1016/S0966-842X(97)01081-0.PubMedView ArticleGoogle Scholar
- Diaz C, Vitezica ZG, Rupp R, Andreoletti O, Elsen JM: Polygenic variation and transmission factors involved in the resistance/susceptibility to scrapie in a Romanov flock. J Gen Virol. 2005, 86 (Pt 3): 849-857. 10.1099/vir.0.80412-0.PubMedView ArticleGoogle Scholar
- Groschup MH, Lacroux C, Buschmann A, Luhken G, Mathey J, Eiden M, Lugan S, Hoffmann C, Espinosa JC, Baron T, et al: Classic scrapie in sheep with the ARR/ARR prion genotype in Germany and France. Emerg Infect Dis. 2007, 13 (8): 1201-1207.PubMed CentralPubMedView ArticleGoogle Scholar
- Le Dur A, Beringue V, Andreoletti O, Reine F, Lai TL, Baron T, Bratberg B, Vilotte JL, Sarradin P, Benestad SL, et al: A newly identified type of scrapie agent can naturally infect sheep with resistant PrP genotypes. Proc Natl Acad Sci USA. 2005, 102 (44): 16031-16036. 10.1073/pnas.0502296102.PubMed CentralPubMedView ArticleGoogle Scholar
- Jeffrey M, Gonzalez L: Classical sheep transmissible spongiform encephalopathies: pathogenesis, pathological phenotypes and clinical disease. Neuropathol Appl Neurobiol. 2007, 33 (4): 373-394. 10.1111/j.1365-2990.2007.00868.x.PubMedView ArticleGoogle Scholar
- Andreoletti O, Berthon P, Marc D, Sarradin P, Grosclaude J, van Keulen L, Schelcher F, Elsen JM, Lantier F: Early accumulation of PrP(Sc) in gut-associated lymphoid and nervous tissues of susceptible sheep from a Romanov flock with natural scrapie. J Gen Virol. 2000, 81 (Pt 12): 3115-3126.PubMedView ArticleGoogle Scholar
- Aguzzi A: Peripheral prion pursuit. J Clin Invest. 2001, 108 (5): 661-662.PubMed CentralPubMedView ArticleGoogle Scholar
- Schreuder BE, van Keulen LJ, Vromans ME, Langeveld JP, Smits MA: Tonsillar biopsy and PrPSc detection in the preclinical diagnosis of scrapie. Vet Rec. 1998, 142 (21): 564-568. 10.1136/vr.142.21.564.PubMedView ArticleGoogle Scholar
- O'Rourke KI, Baszler TV, Besser TE, Miller JM, Cutlip RC, Wells GA, Ryder SJ, Parish SM, Hamir AN, Cockett NE, et al: Preclinical diagnosis of scrapie by immunohistochemistry of third eyelid lymphoid tissue. J Clin Microbiol. 2000, 38 (9): 3254-3259.PubMed CentralPubMedGoogle Scholar
- Monleon E, Monzon M, Hortells P, Bolea R, Acin C, Vargas F, Badiola JJ: Approaches to Scrapie diagnosis by applying immunohistochemistry and rapid tests on central nervous and lymphoreticular systems. J Virol Methods. 2005, 125 (2): 165-171. 10.1016/j.jviromet.2005.01.013.PubMedView ArticleGoogle Scholar
- Espenes A, Press CM, Landsverk T, Tranulis MA, Aleksandersen M, Gunnes G, Benestad SL, Fuglestveit R, Ulvund MJ: Detection of PrP(Sc) in Rectal Biopsy and Necropsy Samples from Sheep with Experimental Scrapie. J Comp Pathol. 2006, 134 (2): 115-125. 10.1016/j.jcpa.2005.08.001.PubMedView ArticleGoogle Scholar
- Langeveld JP, Jacobs JG, Erkens JH, Bossers A, van Zijderveld FG, van Keulen LJ: Rapid and discriminatory diagnosis of scrapie and BSE in retro-pharyngeal lymph nodes of sheep. BMC Vet Res. 2006, 2 (1): 19-10.1186/1746-6148-2-19.PubMed CentralPubMedView ArticleGoogle Scholar
- Monleon E, Garza MA, Sarasa R, Alvarez-Rodriguez J, Bolea R, Monzon M, Vargas MA, Badiola JJ, Acin C: An assessment of the efficiency of PrPsc detection in rectal mucosa and third-eyelid biopsies from animals infected with scrapie. Vet Microbiol.
- Hunter N, Foster J, Chong A, McCutcheon S, Parnham D, Eaton S, MacKenzie C, Houston F: Transmission of prion diseases by blood transfusion. J Gen Virol. 2002, 83 (Pt 11): 2897-2905.PubMedView ArticleGoogle Scholar
- Hsich G, Kenney K, Gibbs CJ, Lee KH, Harrington MG: The 14-3-3 brain protein in cerebrospinal fluid as a marker for transmissible spongiform encephalopathies. N Engl J Med. 1996, 335 (13): 924-930. 10.1056/NEJM199609263351303.PubMedView ArticleGoogle Scholar
- Zerr I, Bodemer M, Racker S, Grosche S, Poser S, Kretzschmar HA, Weber T: Cerebrospinal fluid concentration of neuron-specific enolase in diagnosis of Creutzfeldt-Jakob disease. Lancet. 1995, 345 (8965): 1609-1610. 10.1016/S0140-6736(95)90118-3.PubMedView ArticleGoogle Scholar
- Aksamit AJ, Preissner CM, Homburger HA: Quantitation of 14-3-3 and neuron-specific enolase proteins in CSF in Creutzfeldt-Jakob disease. Neurology. 2001, 57 (4): 728-730.PubMedView ArticleGoogle Scholar
- Otto M, Stein H, Szudra A, Zerr I, Bodemer M, Gefeller O, Poser S, Kretzschmar HA, Mader M, Weber T: S-100 protein concentration in the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. J Neurol. 1997, 244 (9): 566-570. 10.1007/s004150050145.PubMedView ArticleGoogle Scholar
- Beaudry P, Cohen P, Brandel JP, Delasnerie-Laupretre N, Richard S, Launay JM, Laplanche JL: 14-3-3 protein, neuron-specific enolase, and S-100 protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Dement Geriatr Cogn Disord. 1999, 10 (1): 40-46. 10.1159/000017095.PubMedView ArticleGoogle Scholar
- Otto M, Wiltfang J, Tumani H, Zerr I, Lantsch M, Kornhuber J, Weber T, Kretzschmar HA, Poser S: Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Neurosci Lett. 1997, 225 (3): 210-212. 10.1016/S0304-3940(97)00215-2.PubMedView ArticleGoogle Scholar
- Itoh N, Arai H, Urakami K, Ishiguro K, Ohno H, Hampel H, Buerger K, Wiltfang J, Otto M, Kretzschmar H, et al: Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease. Ann Neurol. 2001, 50 (2): 150-156. 10.1002/ana.1054.PubMedView ArticleGoogle Scholar
- Otto M, Wiltfang J, Cepek L, Neumann M, Mollenhauer B, Steinacker P, Ciesielczyk B, Schulz-Schaeffer W, Kretzschmar HA, Poser S: Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt-Jakob disease. Neurology. 2002, 58 (2): 192-197.PubMedView ArticleGoogle Scholar
- Van Everbroeck B, Green AJ, Vanmechelen E, Vanderstichele H, Pals P, Sanchez-Valle R, Corrales NC, Martin JJ, Cras P: Phosphorylated tau in cerebrospinal fluid as a marker for Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry. 2002, 73 (1): 79-81. 10.1136/jnnp.73.1.79.PubMed CentralPubMedView ArticleGoogle Scholar
- Hochstrasser DF, Frutiger S, Wilkins MR, Hughes G, Sanchez JC: Elevation of apolipoprotein E in the CSF of cattle affected by BSE. FEBS Lett. 1997, 416 (2): 161-163. 10.1016/S0014-5793(97)01191-5.PubMedView ArticleGoogle Scholar
- Volkel D, Zimmermann K, Zerr I, Lindner T, Bodemer M, Poser S, Schwarz HP: C-reactive protein and IL-6: new marker proteins for the diagnosis of CJD in plasma?. Transfusion. 2001, 41 (12): 1509-1514. 10.1046/j.1537-2995.2001.41121509.x.PubMedView ArticleGoogle Scholar
- Sanchez JC, Guillaume E, Lescuyer P, Allard L, Carrette O, Scherl A, Burgess J, Corthals GL, Burkhard PR, Hochstrasser DF: Cystatin C as a potential cerebrospinal fluid marker for the diagnosis of Creutzfeldt-Jakob disease. Proteomics. 2004, 4 (8): 2229-2233. 10.1002/pmic.200300799.PubMedView ArticleGoogle Scholar
- Sjogren M: EDRF transcripts and diagnosis of variant Creutzfeldt-Jakob disease. Lancet. 2001, 357 (9274): 2069-2070. 10.1016/S0140-6736(00)05224-7.PubMedView ArticleGoogle Scholar
- Miele G, Manson J, Clinton M: A novel erythroid-specific marker of transmissible spongiform encephalopathies. Nat Med. 2001, 7 (3): 361-364. 10.1038/85515.PubMedView ArticleGoogle Scholar
- Aguzzi A: Understanding the diversity of prions. Nat Cell Biol. 2004, 6 (4): 290-292. 10.1038/ncb0404-290.PubMedView ArticleGoogle Scholar
- Aguzzi A: Neuro-immune connection in spread of prions in the body?. Lancet. 1997, 349 (9054): 742-743. 10.1016/S0140-6736(97)22011-8.PubMedView ArticleGoogle Scholar
- Castilla J, Saa P, Soto C: Detection of prions in blood. Nat Med. 2005, 11 (9): 982-985.PubMedGoogle Scholar
- Castilla J, Saa P, Morales R, Abid K, Maundrell K, Soto C: Protein misfolding cyclic amplification for diagnosis and prion propagation studies. Methods Enzymol. 2006, 412: 3-21. 10.1016/S0076-6879(06)12001-7.PubMedView ArticleGoogle Scholar
- An SS, Lim KT, Oh HJ, Lee BS, Zukic E, Ju YR, Yokoyama T, Kim SY, Welker E: Differentiating scrapie-infected blood by detecting disease-associated prion proteins by Multimer Detection System. Biochem Biophys Res Commun. 2010, 392 (4): 505-509. 10.1016/j.bbrc.2010.01.053.PubMedView ArticleGoogle Scholar
- Terry LA, Howells L, Hawthorn J, Edwards JC, Moore SJ, Bellworthy SJ, Simmons H, Lizano S, Estey L, Leathers V, et al: Detection of PrPsc in blood from sheep infected with the scrapie and bovine spongiform encephalopathy agents. J Virol. 2009, 83 (23): 12552-12558. 10.1128/JVI.00311-09.PubMed CentralPubMedView ArticleGoogle Scholar
- Lacroux C, Simon S, Benestad SL, Maillet S, Mathey J, Lugan S, Corbiere F, Cassard H, Costes P, Bergonier D, et al: Prions in milk from ewes incubating natural scrapie. PLoS Pathog. 2008, 4 (12): e1000238-10.1371/journal.ppat.1000238.PubMed CentralPubMedView ArticleGoogle Scholar
- Clarke CH, Buckley JA, Fung ET: SELDI-TOF-MS proteomics of breast cancer. Clin Chem Lab Med. 2005, 43 (12): 1314-1320. 10.1515/CCLM.2005.225.PubMedGoogle Scholar
- Ardekani AM, Liotta LA, Petricoin EF: Clinical potential of proteomics in the diagnosis of ovarian cancer. Expert Rev Mol Diagn. 2002, 2 (4): 312-320. 10.1586/14737220.127.116.112.PubMedView ArticleGoogle Scholar
- Abdul-Salam VB, Paul GA, Ali JO, Gibbs SR, Rahman D, Taylor GW, Wilkins MR, Edwards RJ: Identification of plasma protein biomarkers associated with idiopathic pulmonary arterial hypertension. Proteomics. 2006, 6 (7): 2286-2294. 10.1002/pmic.200500510.PubMedView ArticleGoogle Scholar
- Meade-White KD, Barbian KD, Race B, Favara C, Gardner D, Taubner L, Porcella S, Race R: Characteristics of 263 K scrapie agent in multiple hamster species. Emerg Infect Dis. 2009, 15 (2): 207-215. 10.3201/eid1502.081173.PubMed CentralPubMedView ArticleGoogle Scholar
- Tusher VG, Tibshirani R, Chu G: Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA. 2001, 98 (9): 5116-5121. 10.1073/pnas.091062498.PubMed CentralPubMedView ArticleGoogle Scholar
- Zweig MH, Campbell G: Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem. 1993, 39 (4): 561-577.PubMedGoogle Scholar
- Kramar A, Faraggi D, Fortune A, Reiser B: mROC: a computer program for combining tumour markers in predicting disease states. Comput Methods Programs Biomed. 2001, 66 (2-3): 199-207. 10.1016/S0169-2607(00)00129-2.PubMedView ArticleGoogle Scholar
- Y F: Experiments with a New Boosting Algorithm. International Conference on Machine Learning: 1996. 1996Google Scholar
- Vapnik V, Chapelle O: Bounds on error expectation for support vector machines. Neural Comput. 2000, 12 (9): 2013-2036. 10.1162/089976600300015042.PubMedView ArticleGoogle Scholar
- Vapnik VN: An overview of statistical learning theory. IEEE Trans Neural Netw. 1999, 10 (5): 988-999. 10.1109/72.788640.PubMedView ArticleGoogle Scholar
- Box GEP, Cox DR: An analysis of transformations. JRSS B. 1964, 26: 211-246.Google Scholar
- Dessau RB, Pipper CB: [''R"--project for statistical computing]. Ugeskr Laeger. 2008, 170 (5): 328-330.PubMedGoogle Scholar
- Proteomic database. [http://www.expasy.org]
- Hybelova M, Svatonova J, Sobek O, Adam P, Dolezil D, Adam D: Cerebrospinal fluid and serum prealbumin (transthyretin) in patients with multiple sclerosis (MS): comparison of particular subgroups of MS patients. Folia Microbiol (Praha). 2009, 54 (2): 173-176. 10.1007/s12223-009-0027-4.View ArticleGoogle Scholar
- Dardiotis E, Koutsou P, Papanicolaou EZ, Vonta I, Kladi A, Vassilopoulos D, Hadjigeorgiou G, Christodoulou K, Kyriakides T: Epidemiological, clinical and genetic study of familial amyloidotic polyneuropathy in Cyprus. Amyloid. 2009, 16 (1): 32-37. 10.1080/13506120802676948.PubMedView ArticleGoogle Scholar
- Li YF, Ng H, Sun IU, Leong W: Clinical and genetic analysis of three families with familiar amyloid polyneuropathy. Chin Med Sci J. 2008, 23 (4): 230-233. 10.1016/S1001-9294(09)60044-4.PubMedView ArticleGoogle Scholar
- Ueda M, Misumi Y, Mizuguchi M, Nakamura M, Yamashita T, Sekijima Y, Ota K, Shinriki S, Jono H, Ikeda S, et al: SELDI-TOF mass spectrometry evaluation of variant transthyretins for diagnosis and pathogenesis of familial amyloidotic polyneuropathy. Clin Chem. 2009, 55 (6): 1223-1227. 10.1373/clinchem.2008.118505.PubMedView ArticleGoogle Scholar
- Gloeckner SF, Meyne F, Wagner F, Heinemann U, Krasnianski A, Meissner B, Zerr I: Quantitative analysis of transthyretin, tau and amyloid-beta in patients with dementia. J Alzheimers Dis. 2008, 14 (1): 17-25.PubMedGoogle Scholar
- Golanska E, Gresner S, Sieruta M, Liberski P: [Cerebrospinal fluid markers of prion diseases]. Neurol Neurochir Pol. 2008, 42 (5): 441-450.PubMedGoogle Scholar
- Vicente H, Outeiro TF: The sour side of neurodegenerative disorders: the effects of protein glycation. J Pathol. 2010, 221 (1): 13-25.View ArticleGoogle Scholar
- Apweiler R, Aslanidis C, Deufel T, Gerstner A, Hansen J, Hochstrasser D, Kellner R, Kubicek M, Lottspeich F, Maser E, et al: Approaching clinical proteomics: current state and future fields of application in fluid proteomics. Clin Chem Lab Med. 2009, 47 (6): 724-744. 10.1515/CCLM.2009.167.PubMedView ArticleGoogle Scholar
- Barr JB, Watson M, Head MW, Ironside JW, Harris N, Hogarth C, Fraser JR, Barron R: Differential protein profiling as a potential multi-marker approach for TSE diagnosis. BMC Infect Dis. 2009, 9: 188-10.1186/1471-2334-9-188.PubMed CentralPubMedView ArticleGoogle Scholar
- Johnson CJ, Pedersen JA, Chappell RJ, McKenzie D, Aiken JM: Oral Transmissibility of Prion Disease Is Enhanced by Binding to Soil Particles. PLoS Pathog. 2007, 3 (7): e93-10.1371/journal.ppat.0030093.PubMed CentralPubMedView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.